Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a change in shareholding by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific equity transaction.
| Metric | Value |
|---|---|
| Transaction Type | Dividend Re-investment (2009 Performance Share Plan) |
| Instrument | Ordinary Shares (ISIN: GB0009252882) |
| Transaction Date | July 14, 2016 |
| Share Price | £16.285 |
| Total Volume Acquired | 7,337.467 shares |
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares held by Mr. S Dingemans, the Chief Financial Officer. This increase resulted from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Performance Share Plan. No other material changes to the company's operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a director's transaction.
Key Facts for Investor Verification
- Insider Activity: CFO S Dingemans increased his shareholding via dividend re-investment.
- Transaction Volume: Approximately 7,337 shares were acquired at a price of £16.285 per share.
- Plan Context: The transaction occurred under the 2009 Performance Share Plan.
- Financial Data: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or earnings releases for financial metrics.